1. Novel oral anticoagulant and kidney injury: apixaban-related acute interstitial nephritis
- Author
-
Abhinav Goyal, Basma Abdulhadi, Janani Rangaswami, and Ramzi Mulki
- Subjects
medicine.medical_specialty ,medicine.drug_mechanism_of_action ,Pyridones ,Factor Xa Inhibitor ,Administration, Oral ,Context (language use) ,030204 cardiovascular system & hematology ,Dabigatran ,Diagnosis, Differential ,03 medical and health sciences ,0302 clinical medicine ,Atrial Fibrillation ,medicine ,Humans ,030212 general & internal medicine ,Intensive care medicine ,Aged ,Acute interstitial nephritis ,business.industry ,Acute kidney injury ,Anticoagulants ,Atrial fibrillation ,General Medicine ,Acute Kidney Injury ,medicine.disease ,Acute Disease ,Nephritis, Interstitial ,Pyrazoles ,Female ,Apixaban ,Differential diagnosis ,business ,Findings That Shed New Light on the Possible Pathogenesis of a Disease or an Adverse Effect ,Factor Xa Inhibitors ,medicine.drug - Abstract
Non-vitamin K oral anticoagulants (NOACs) are being increasingly prescribed. These drugs act rapidly, have predictable dose-related anticoagulation effect and require no routine laboratory monitoring, making them attractive for both patients and healthcare providers. All NOACs are at least partially excreted thought the kidneys. Renal injury related to NOAC use is being increasingly reported. NOAC-related acute interstitial nephritis (AIN) has only been reported once and that was in context of dabigatran use. We describe the first case of apixaban-related AIN. This case adds an important differential diagnoses that should be considered for any patient presenting with renal injury while being treated with NOACs.
- Published
- 2017
- Full Text
- View/download PDF